Altimmune logo
Altimmune
ALT | NASDAQ
Chart Builder DCF Calculator
$1.56
-$0.08 (-5.17%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.01 (+0.64%)
After-hours: Nov 16, 2026, 7:57 PM ET

Altimmune Company Profile

Company profile explained

Company Profile

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Key Executives

Name Position
Jerome Benedict Durso Chairman, CEO & President
Bertrand Georges Chief Technology Officer
Gregory L. Weaver Chief Financial Officer
Robin E. Abrams Chief Legal Officer & Corporate Secretary
Andrew Shutterly Principal Financial & Accounting Officer and Corporate Controller
Christophe Arbet-Engels Chief Medical Officer
Linda Richardson Chief Commercial Officer
Luis Sanay Vice President of Investor Relations
Raymond Jordt Chief Business Officer
Richard Menziuso VP, Global Controller & Principal Accounting Officer
Scot Roberts Chief Scientific Officer
Tony Blandin Vice President of Quality & Compliance Management

Latest SEC Filings

Date Type Title
Oct 29, 2026 8-K Current Report
Oct 27, 2026 8-K Current Report
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 3 Filing
Sep 29, 2026 8-K Current Report
Sep 17, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 12, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Altimmune
Altimmune logo
Country United States
IPO Date May 26, 2017
Industry Biotechnology
Sector Healthcare
Employees 57
CEO Jerome Benedict Durso

Contact Details

910 Clopper Road Gaithersburg, Maryland 20878 United States

Stock Details

Ticker Symbol ALT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001326190
CUSIP Number 02155H200
ISIN Number US02155H2004
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.